SCHEMBL362127

SCHEMBL362127

Cc1nc(C(=O)Nc2cc(Br)cc(C3(C)COCC(N)=N3)c2)c(C)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 1.00
APP P05067 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL362528 1.00 BACE1 (1.00) BACE1APP
SCHEMBL360699 0.86 BACE1 (1.00) BACE1APP
SCHEMBL16390627 0.84 BACE1 (0.73) BACE1APP
SCHEMBL360399 0.83 BACE1 (1.00) BACE1APP
SCHEMBL360426 0.83 BACE1 (1.00) BACE1APP
SCHEMBL362188 0.83 BACE1 (1.00) BACE1APP
SCHEMBL363281 0.83 BACE1 (1.00) BACE1APP
SCHEMBL360955 0.81 BACE1 (1.00) BACE1APP
SCHEMBL362141 0.81 BACE1 (1.00) BACE1APP
SCHEMBL15678382 0.81 BACE1 (0.85) BACE1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011009943-A1 OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS NOVARTIS AG (CH) 2011-01-27 WO disclosed